OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate

Urology

Volumn 45, Issue 1, 1995, Pages 81-86

  Epstein, Jonathan I ^a,b   Carmichael, Marné ^a,b   Partin, Alan W ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; PROSTATE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; SEMINAL VESICLE;

ADENOCARCINOMA; BLOOD PROTEINS; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0028875706     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(95)96904-7     Document Type: Article

References (22)

1. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
2. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
3. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer
4. Fatty acid synthesis: a potential selective target for antineoplastic therapy
5. Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization
6. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease
7. Expression of haptoglobin-related protein in primary and metastatic breast cancers
8. Correlation of pathologic findings with progression after radical retropubic prostatectomy
9. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate
10. Aid to accurate clinical staging—histopathologic grading in prostatic cancer
11. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression
12. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma
13. p53 is mutated in a subset of advanced-stage prostate cancer
14. p53 oncogene mutations in human prostate cancer specimens
15. Expression of the c-erbB2 (HER-2/neu) oncoprotein in human prostatic carcinoma
16. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
17. Overexpression of HER-2/NEU may be an indicator of poor prognosis in prostate cancer
18. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma
19. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma
20. Predictions of pathologic stage in prostatic carcinoma: the role of neovascularity
21. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator